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Medicine and Montefiore Medical Center, Bronx, New YorkMitral valve repair is considered the procedure of choice
for correcting mitral regurgitation in myxomatous dis-
ease, providing long-term results that are superior to
those with valve replacement. The use of artificial chor-
dae to replace elongated or ruptured chordae responsible
for mitral valve prolapse and severe mitral regurgitation
has been the subject of extensive experimental work to
define feasibility, reproducibility, and effectiveness of
this procedure. Artificial chordae made of autologous or
xenograft pericardium have been replaced by chordae
made of expanded polytetrafluoroethylene (PTFE), a ma-
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 by ats.ctsnetjournals.orgDownloaded from terial with the unique property of becoming covered by
host fibrosa and endothelium. The use of artificial chor-
dae made of PTFE has been validated clinically over the
past 2 decades and has been an increasing component of
the surgical armamentarium for mitral valve repair. This
article reviews the history, details of the relevant surgical
techniques, long-term results, and fate of artificial chor-
dae in mitral reconstructive surgery.
(Ann Thorac Surg 2012;93:684–91)
© 2012 by The Society of Thoracic SurgeonsThere is strong evidence that mitral valve repair fordegenerative valve disease is superior to mitral
valve replacement [1, 2]. Very long-term results of mitral
valve repair have shown that this procedure, maintaining
both valvular tissue and the subvalvular apparatus, has a
lower operative mortality, with better preservation of left
ventricular function and superior survival rates, than
does prosthetic valve replacement [3]. These results sug-
gest an indication for early mitral valve repair in asymp-
tomatic patients and in patients without signs of left
ventricular dysfunction [4]. Techniques for mitral valve
repair have been popularized by the pioneering work of
Carpentier [5], who described various methods of mitral
valve reconstruction based on a new pathophysiologic
classification. Among these methods, particular attention
was given to the treatment of elongated or ruptured
chordae, which is a common pathologic finding in pa-
tients with both fibroelastic deficiency and those with
more complex Barlow disease of the mitral valve [6]. The
techniques of leaflet fixation on secondary chordae,
chordal transposition, and chordal shortening that Car-
pentier proposed [5] were undoubtedly appealing, but
also technically quite demanding and not easily repro-
ducible. Furthermore the reported results generated con-
flicting opinions about the effectiveness of these tech-
niques [7, 8], particularly because the repaired chordae
are still diseased and may again elongate or rupture with
Address correspondence to Dr Bortolotti, Sezione Autonoma di Car-time, leading to recurrent mitral regurgitation. For this
reason, there has been recent renewed interest in the use
of artificial sutures to replace diseased native mitral
chordae. This paper reviews the history, surgical tech-
niques, and long-term results for such chordal replace-
ment, and discusses the fate of artificial chordae on the
basis of available pathologic data.
Material and Methods
A search of the Medline and PubMed databases was
conducted for articles in the English language, supple-
mented by information obtained from archives of the jour-
nals available on the CTSNet website and from personal
files. Pertinent articles were selected on the basis of the
following keywords: mitral valve repair, mitral valvulo-
plasty, mitral chordae replacement, artificial chordae, ex-
panded polytetrafluoroethylene sutures, and Gore-Tex su-
tures. Articles containing information on the use of artificial
chordae, in terms of technical details, pathology, and results
of their use, were considered in this review; also included,
for comparison, were articles reporting the long-term re-
sults ofmitral valve repair using various techniques, with or
without chordal replacement.
History
The Use of Pericardium
In patients with degenerative mitral valve disease, mitral
incompetence is most often a consequence of the elon-
gation or rupture of chordae tendineae, or both [9, 10].
0003-4975/$36.00
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WSuccessful repair in this condition was occasionally
achieved by direct suture of the affected chorda or leaflet
to the papillary muscle, or by chordal replacement with
various types of sutures (silk, nylon, mersilene, or other,
unspecified materials) as shown by scattered case reports
or small clinical series in the early or mid-1960s [11–19]. It
is unclear why such suture materials were not effective
for chordal replacement. Some of the patients treated
with such sutures did not survive operation and others
underwent reoperation because of technical failures. In-
deed, the reported follow-up of patients who survived
has been quite limited, and information about the fate of
the various suture materials used in repairing their
chordae is lacking. In 1949, Templeton and colleagues
reported the use of pericardial tissue to reconstruct
cardiac valves [20]. They replaced a cusp of the tricuspid
valve in dogs with a graft of fresh, autologous pericar-
dium shaped to contain a rudimentary chorda that was
attached to a stump of a papillary muscle. Early results
showed that this type of graft maintained function and
flexibility in most animals. Other investigators demon-
strated the feasibility of mitral valve repair, both exper-
imentally and clinically, done with various techniques
and differently shaped pericardial grafts [21–23]; how-
ever, in the oldest specimens the grafts appeared almost
invariably thickened, fibrosed, and shrunken.
In 1964 Frater reported the anatomic rules for repair of
a diseased mitral valve [24]. These were based on thor-
ough review of the basic anatomy of normal canine and
human mitral valves, with a particular focus on the role
played by the chordae tendineae. The essential observa-
tion was that although the leaflets had irregular shapes
and lengths that varied from one leaflet segment to
another, and although the chordae had varied origins
and lengths, the free edges of the anterior and posterior
leaflets were always parallel wherever they met. If a
chorda became too long, the free edge it supported
would slide up toward the atrium and normal coaptation
would be lost. Knowledge of this made it possible to
determine the proper length of a neochorda: the proper
length was the length that kept the anterior and posterior
free edges parallel when they were in the straight lines
they assumed during systole. These rules were validated
by replacing the posterior mitral leaflet and chordae with
autologous pericardium both experimentally and clini-
cally [25]. The results showed that the pericardium im-
planted in dogs retained early flexibility but was thick-
ened and contracted in older explants. This technique
was applied in 7 patients, who had implantation of a
posterior pericardial cusp with chordal sheets with good
early hemodynamic results. By 1969, however, it was
apparent that the pericardium had lost function because
of excessive fibrous healing [26].
Interest in the use of pericardium in replacing rup-
tured mitral chordae was renewed by the work of Ritten-
house and coworkers in 1978 [27]. This technique was
applied clinically in 10 patients with severe mitral regur-
gitation, in whom strips of autologous pericardium were
attached to the papillary muscles and then to the free
margin of the mural mitral leaflet, yielding in most cases
 by ats.ctsnetjournals.orgDownloaded from chordae of approximately 2 cm in length. Rittenhouse
and coworkers’ early results were excellent, with almost
complete resolution of mitral regurgitation in all 10
patients and with improved clinical status (to New York
Heart Association class I) for up to 3 years in the 9
patients who survived hospitalization. Encouraged by
these results, Frater and associates, now at the Albert
Einstein College of Medicine in New York City, resumed
both their animal experiments and clinical applications.
The implantation in dogs of chordae of xenograft peri-
cardium showed that pliability was retained in early
explants, with various degrees of fibrosis and calcification
at 12 months [28]. When implanted in a series of 11
patients, pericardial neochordae gave satisfactory results,
allowing the conclusion that this technique was repro-
ducible and maintained valve competence for up to 3
years [28]. Further experiments were then conducted at
the Albert Einstein College of Medicine to test the
difference between untreated and glutaraldehyde-
treated autologous pericardium and glutaraldehyde-
treated xenograft pericardium in dogs and sheep [29, 30].
In these experiments, strips of pericardium were shaped
to replicate the intercordal spaces, and were attached to
papillary muscles and both the anterior and posterior
mitral leaflets (Fig 1). All neochordae showed good heal-
ing at both ends, retaining their original length (Fig 2).
Untreated autologous pericardium became uniformly
fibrosed and stiff, treated autologous pericardium had
a marked fibrous reaction at the healing ends but
retained its pliability, and xenograft pericardium be-
came stiffened; calcification was observed in all long-
term explants [29, 30].
The Use of Expanded Polytetrafluoroethylene
Although the work described above clearly demon-
strated the feasibility of chordal replacement, the long-
term fate of pericardium as a potential chordal substitute
was questionable, indicating the need for a longer-lasting
material with which to create neochordae. The stimulus
for investigating expanded polytetrafluoroethylene
(ePTFE) for this purpose came from the observation that
although arterial grafts made of GoreTex (Gore-Tex, WL
Gore and Associates, Inc., Flagstaff, AZ) did not acquire
an inner host covering, the first 1 to 2 mm were seen to
have a host covering of fibrous and endothelial tissue.
Gaps in the structure of ePTFE, known as “intermodal
spaces,” had provided attachment of the material to
fibroblasts. This led to the belief that an ePTFE suture
with the same spaces might gain a covering of host tissue.
Vetter tested ePTFE sutures in sheep, and by 5 months
the host sheep had grown new chordae over the template
provided by the suture [31].
Expanded polytetrafluoroethylene is a thermoplastic
polymer used in a wide variety of applications. It has
outstanding physical, chemical, mechanical, and thermal
properties, and in particular is flexible, with a high tensile
strength and resistance to fatigue. The suture material
made of ePTFE is a microporous, nonabsorbable, mono-
filament that, owing to its mechanical and biologic prop-
erties, appeared to be an ideal material for constructing
Uberto Bortolotti on February 6, 2012 
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However, in the initial experiments with ePTFE done by
Vetter and colleagues [31] in sheep CV2 Gore-Tex (the
equivalent of 2-0 conventional sutures) with a host tissue
covering showed significantly reduced chordal flexibility.
Subsequently, at the same institution, Zussa and associ-
ates [32] conducted a study in which CV5 ePTFE sutures
Fig 1. One of the techniques used to replace
mitral valve chordae in animal experiments at
Albert Einstein College of Medicine in the
early 1980s. (A) A drawing of the procedure
used to compare autologous and xenograft
pericardium. Usually, two pairs of pericardial
chordae (approximately 2.5 cm of length and
0.5 cm of width) were first sutured to the tip
of each papillary muscle and then to the free
margin of the posterior mitral leaflet. (B) The
strips of autologous and xenograft pericardium
before implantation with creation of inter-
cordal spaces (white arrows).
Fig 2. Gross view of explanted hearts after short-term animal sacri-
fice. (A) The white arrows indicate the pericardial neochordae which
retained their original length. (B) Closer view of the anterior mitral
leaflet with two pericardial chordae (white arrows).
 by ats.ctsnetjournals.orgDownloaded from used both in dogs and sheep provided good healing at
the papillary muscle level as well as on the cusp side of
the mitral valve. On histologic examination for up to 13
months after implantation, the sutures appeared to be
progressively and uniformly covered by fibrous tissue
with a neointimal cellular sheath and without signs of
calcification. All of the chordae made of ePTFE main-
tained their original length, pliability, and bending prop-
erties. These results were replicated by Revuelta and
colleagues [33], who confirmed at electron microscopy
that ePTFE chordae implanted in sheep were completely
covered by tissue with a collagen structure resembling
that of a native chorda.
After the provision of experimental evidence that
ePTFE sutures could be safely used to replace diseased
mitral chordae, clinical application of this technique was
begun for treating patients with degenerative mitral
valve pathology, and extending to patients with rheu-
matic disease [32, 34]. Early results of this technique were
gratifying, leading to the consideration that it was sim-
pler than chordal transfer and the expectation that it
would become the procedure of choice after the durabil-
ity of ePTFE had been proven [35].
Surgical Techniques
Each two-armed Gore-Tex suture allows the creation of a
pair of neochordae. Recently, techniques have been pro-
posed by which multiple chordae can be obtained by
using premeasured Gore-Tex loops [36–38]. In this tech-
nique, 4-0 to 6-0 sutures are usually used to construct as
many chordae as considered necessary. In the original
technique, ePTFE sutures were attached to a papillary
muscle in a mattress fashion, with reinforcement by
Teflon pledgets on both sides, and were then tied [32].
The two ends of the suture were fixed separately at the
free margin of the mitral leaflet, with the stitch brought
through the edge and tied around a metal clip or a small
ePTFE pledget. Revuelta and associates used a similar
technique [33], differing in that both arms of the suture
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Wwere brought to the free edge of the leaflet and then
woven into the leaflet toward the annulus, where they
were tied on a pledget. Many surgeons have adopted
such a technique and it has remained fairly standardized.
Major variations have included the use of a single
pledget at the papillary muscle attachment of the suture,
the use of pericardial or ePTFE pledgets instead of Teflon
pledgets, and the non-use of pledgets [39–42].
On the leaflet side, sutures are usually passed at least
twice on the free margin of the prolapsed leaflet and then
tied on the atrial or ventricular side. According to each
surgeon’s preference, the suture on the leaflet side can be
reinforced with small pledgets, particularly if the free
margin of the leaflet appears fragile. Prolapsing leaflets
commonly have jet lesion-induced thickening of their
free edges, which have sufficient strength to hold the
sutures well. However, Gore-Tex is slippery, and sur-
geons have sometimes found that the carefully chosen
lengths of ePTFE neochordae have become too short after
the suture knot is tied. Some surgeons build multirow
knot towers to avoid this problem. There appear to be no
consequences of this practice apart from an unaesthetic
appearance. The avoidance of this problem is achieved in
one of the two following ways: (1) The suture is locked as
the knot is begun. There are multiple techniques for
doing this, but once locked, the suture can be tied firmly
enough to produce the compression of the thread that
produces the friction that prevents it from slipping. (2)
The free edge of the leaflet is held under tension at the
correct height while the knot is tied. Among many
methods for achieving this, placement of a nitinol clip
has been shown to be effective and safe [43, 44].
A prerequisite for achieving mitral valve competence is
the correct sizing of artificial chordae. The basic principle
in this is that during systole, with the chordae in straight
lines, the apposing edges of the mitral valve are normally
at the same level. Since the chordae are also under
tension in diastole [45], it is possible in the arrested heart
to insert, under tension, a chorda of normal length
opposite a rupture and to choose a new chorda of a
length that keeps the edges of the valve leaflets parallel
to one another. The ingenuity of surgeons around the
world has produced multiple effective solutions for
achieving this goal. The simplest method appears to be
that used in early experiments or clinical applications [33,
35, 46]. In this method, the chordae have been sutured
in place and the left ventricle is filled under pressure
until perfect leaflet apposition is obtained. The sutures
can then be gently pulled until valve competence is
achieved, and can then be tied. This technique has
maintained its validity with time, and with certain
modifications is still currently successfully used [41, 42,
47–49].
Measurement of the length of artificial chordae may be
done preoperatively by means of transesophageal echo-
cardiography. Calafiore suggested such measurement by
echographic measurement of the distance between the
plane of the mitral annulus and the edge of the prolaps-
ing mitral leaflet. The length of the artificial chorda is
obtained by subtracting the length of the elongated m
 by ats.ctsnetjournals.orgDownloaded from chorda, measured intraoperatively with a ruler, from the
initial measurement [50]. Mandegar and coworkers have
proposed drawing a line between the base of the anterior
and posterior mitral leaflets and calculating the distance
between the head of the posterior papillary muscle and
the line at the coaptation of the leaflets [51]. Others have
favored the intraoperative use of calipers to obtain the
correct length of artificial neochordae [36, 37, 52]. More
recently, there has been clinical validation of techniques
that allow intraoperative adjustment of the length of
artificial chordae until perfect coaptation of the mitral
leaflet is obtained [53, 54].
There is common agreement that the use of ePTFE
chordae should be associated to other repair procedures,
particularly in the correction of complex mitral valve
disease. Although most surgeons favor the routine use of
an annuloplasty ring, excellent midterm results have
been obtained with the use of artificial chordae for both
anterior and posterior leaflet prolapse without ring an-
nuloplasty [55]. It must, however, be emphasized that the
results of this latter approach are at variance with those
in most other studies, which suggest a decreased dura-
bility of repair when annuloplasty is not done [56, 57]. A
further point is the need to emphasize the fundamental
role of intraoperative echocardiography in assessing
valve pathology, in guiding surgical procedures, and in
evaluating the adequacy and effectiveness of mitral valve
repair.
Long-Term Results
The results of mitral valve repair have been excellent for
periods of up to 20 years both in terms of patient survival
and the stability of repair [3, 4]. However, most reports of
such repair in the literature present its results as cumu-
lative data, without stratification according to the tech-
nique used, which prevents full evaluation of the effect of
artificial chordae on the outcomes of such repair. David
and associates reported their experience with mitral
valve repair with and without chordal replacement [39].
t 10 years there was 75% survival, 96% freedom from
eoperation, and 93% freedom from severe recurrent
itral regurgitation. According to David and associates’
tatistical analysis, chordal replacement had no effect on
hese endpoints [39].
Although ePTFE chordae have been used in mitral
alve repair surgery for more than two decades, data on
he long-term clinical results of this technique are lim-
ted, with few papers reporting results of 10 or more
ears of follow-up. Kobayashi and colleagues described
4 patients undergoing mitral valve repair with ePTFE
utures, with an operative mortality of 1.4% [40]. At 12
ears they observed an actuarial survival of 89% and an
2% freedom from reoperation. They attributed their
igher reoperation rate as compared with that of others
o a large number of patients with more complex disease,
ith bileaflet prolapse, and to the initial lack of adoption
f ring annuloplasty. However, none of their cases of
ecurrent mitral regurgitation were caused by rupture or
alfunction of artificial chordae. Kasegawa and associ-
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IEWates, in 2006, reported a 12-year follow-up of the repair of
anterior mitral leaflet prolapse with ePTFE chordae [41].
mong 236 patients with severe mitral regurgitation,
PTFE chordae were used in 204 patients, with a 1.4%
0-day mortality. At 12 years. survival and freedom from
eoperation were 85% and 90%, respectively. The longest
ollow-up so far available, and the one involving the
argest series of patients, is that conducted by Salvador
nd coworkers [42], who reported a 20-year experience
ith mitral valve repair using artificial chordae in 608
atients. In their series, chordae made of ePTFE were
sed in the repair of a wide variety of mitral valve
athologies, most of which were degenerative, with an
perative mortality below 1%. Data at 15 years of fol-
ow-up indicate an 84% actuarial survival, a 92% freedom
rom reoperation, and an 85% freedom from severe
itral regurgitation. Again no cases of primary failure of
PTFE chords were observed.
All these excellent results clearly indicate that chordal
eplacement can be successfully applied to a variety of
natomic situations and provides effective and stable
itral repair. Recently, Perier and coworkers presented
he results of a more conservative approach to the recon-
truction of posterior mitral leaflet prolapse, using arti-
cial chordae without tissue resection [58]. At 10 years
f follow-up, they reported an 87% survival, which was
he same as that for the general population matched
or age and sex, and a 93% freedom from reoperation.
arious studies have shown that the midterm results of
he repair of prolapse of the posterior mitral leaflet
ith either quadrangular resection or the use of arti-
cial chordae are equivalent [59–61]. However, in a
andomized prospective trial, Falk and coworkers [59]
ould demonstrate a significantly longer line of leaflet
oaptation after the implantation of ePTFE loops than
fter leaflet resection. Early and midterm echocardio-
raphic follow-up revealed excellent valve function in
he majority of their patients, with no significant dif-
erence in mitral orifice area from that with leaflet
esection [59].
Satisfactory results were also obtained with the use of
rtificial chordae in children, although the experience in
his patient population is much more limited than that
ith adults. Early data supported the use of Gore-Tex
utures for repairing various mitral valve malformations
n children [62, 63]. Over the long range, freedom from
eoperation at 15 years was as low as 80%, probably
wing to the severity of mitral disease and complexity of
epair in children, although no reoperation was necessi-
ated by chordal malfunction [64].
The extended experience acquired with artificial chor-
ae made of ePTFE for mitral valve repair has allowed its
se for different purposes. Thus, for example, Sintek and
honsari reported the use of ePTFE chordae to re-
stablish annular papillary connection after complete
alve excision during mitral valve replacement, demon-
trating the versatility of ePTFE in addition to its other
roperties [65].
 by ats.ctsnetjournals.orgDownloaded from Pathology Associated With the Use of ePTFE
Chordae
Because of the excellent long-term durability of mitral
valve repair with ePTFE sutures, little is known about the
structural changes observed in artificial chordae im-
planted in patients, although some information about
this can be obtained from a few reports of clinical and
pathologic findings. The early changes observed in ePTFE
sutures are similar to those observed in animal experi-
ments, indicating that artificial chordae made of ePTFE
soon become covered by fibrous tissue, although with a
slower rate of host tissue overgrowth [32]. Others ob-
served an early proliferation of fibroblasts without a
detectable endothelial layer [66]. In intermediate-term
observations, made from 6 to 9 years after implantation,
ePTFE chordae usually kept their flexibility, being encap-
sulated with fibrous tissue covered with endothelium,
but without calcification [67, 68]. Although there are data
to the effect that even after 10 years ePTFE chordae are
still flexible and pliable, or have extensive fibrosis that
makes them indistinguishable from native chordae [42],
there is evidence that with the progression of time,
artificial chordae may degenerate, calcify, and eventually
rupture (Fig 3). The first case of ruptured ePTFE chordae
as cause of recurrent mitral regurgitation was described
by the Toronto group in 2004 [68]. In this case, calcifica-
tion led to chordal rupture 14 years after the repair of
damage from rheumatic mitral valve disease. Subse-
quently, Coutinho and associates reported two similar
cases, occurring 6 and 11 years after the repair of myxo-
matous mitral incompetence [69]; in the one case in
which histologic findings were available, calcification of
the synthetic material was observed. Farivar and col-
leagues reported the case of a patient in whom severe
hemoglobinuria was caused by recurrent mitral regurgi-
tation from a ruptured artificial chorda 11 years after its
insertion; unfortunately, no pathologic data were pro-
vided in this case [70]. Fukunaga and coworkers pre-
sented the case of a patient with dystrophic calcification
of ePTFE sutures causing chordal shortening and recur-
Fig 3. Rupture of an ePTFE chorda, causing severe recurrent mitral
regurgitation in a patient approximately 11 years after mitral valve
repair. Arrows indicate the torn chordae, which connected to the an-
terior mitral leaflet.
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Wrent mitral incompetence from loss of coaptation of the
mitral leaflets [71]. Features common to the reported
cases of ePTFE-related pathology indicate that with time,
a fibrous reaction may be a potential site of dystrophic
calcification that weakens the ePTFE, causing chordal
failure. Interestingly enough, no cases of calcification of
Gore-Tex chordae have so far been reported in the
pediatric population.
Available clinical data and the limited number of
pathology reports related to their use have documented
excellent durability and a low rate of structural deterio-
ration of ePTFE chordae. However, it must be recognized
that many patients with valve failure following mitral
valve repair may not undergo reoperation, and the true
incidence of artificial chordae failure may therefore be
underestimated. On the other hand, it must be also be
emphasized that recurrent mitral regurgitation from
chordae that are too long or inappropriately placed must
not be considered as failures of ePTFE but essentially as
technical errors.
Conclusion
Mitral valve repair is the procedure of choice to correct
mitral regurgitation for myxomatous disease, yielding
long-term results that are superior to those with valve
replacement. The use of artificial ePTFE chordae is an
established method for addressing the problem of elon-
gated or ruptured chordae causing mitral valve prolapse.
This technique appears to be safe, effective, and repro-
ducible, and has become a useful additional tool among
the many tools needed for the repair of most cases of
degenerative mitral valve disease. However, the use of
artificial ePTFE chordae requires a learning curve that is
difficult to quantify and can be extremely variable. In-
deed, learning curves, particularly in the field of mitral
valve repair, depend not only on each surgeon’s experi-
ence and case exposure but also on the complexity of the
disease.
Review of the experimental and clinical experience
acquired with the use of ePTFE in mitral valve repair
allows the following conclusions:
1. Classical techniques led the way in establishing
repair as the optimal mode of handling degenera-
tive mitral valve disease.
2. The use of ePTFE chordae is by now securely
established as reproducible and durable. It has
enabled some surgeons to increase the number of
effective repairs of mitral valve disease, and is now
an essential part of the wide array of techniques
needed for the conservative treatment of a greater
number of cases of even extremely complex mitral
valve disease. In fact, according to David and asso-
ciates [72] the use of artificial chordae was the
single most important factor in making mitral valve
repair feasible in most patients with mitral insuffi-
ciency caused by leaflet degeneration, ranging from
degeneration caused by fibroelastic deficiency to
that caused by severe Barlow disease.
 by ats.ctsnetjournals.orgDownloaded from . A wide variety of technical solutions have been
adopted for mitral valve repair with the use of
artificial chordae, with particular attention directed
at defining their correct length.
. It can be foreseen that the use of artificial chordae
for mitral valve repair will have wide future adop-
tion should a “nonresectional approach” to mitral
valve repair [54] become widely accepted.
. It has been documented that ePTFE can occasion-
ally fail over the long-term because of calcification.
Thus, as follow-up of such patients increases. Con-
sequently, the careful and continuous echocardio-
graphic surveillance of patients with ePTFE chordae
appears justified and mandatory as the duration of
their follow-up increases.
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